New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 250mg;   - capsule - 250 mg - active: didanosine 250mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint blue sb-6018 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 400mg;   - capsule - 400 mg - active: didanosine 400mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer opacode red s-1-15094 opacode red s-1-15095 purified talc sodium starch glycolate titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - nivolumab; relatlimab - concentrate for solution for infusion - relatlimab 4 mg/ml; nivolumab 12 mg/ml - nivolumab - opdualag is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - abatacept 262.5mg;  ;   - powder for injection - 250 mg - active: abatacept 262.5mg     excipient: hydrochloric acid maltose monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.) orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - abatacept 125.875mg equivalent to abatacept 125mg/ml;  ;   - solution for injection - 125 mg - active: abatacept 125.875mg equivalent to abatacept 125mg/ml     excipient: dibasic sodium phosphate monobasic sodium phosphate nitrogen poloxamer 188 sucrose water for injection - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progress of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthiritis in adults not previously treated with methotrexate. orencia should not be administered concurrently with other dmards (eg. tnf inhibitors, rituximab or anakinra).

Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - nivolumab - infusion, solution concentrate - nivolumab 10 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - ipilimumab -

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - ipilimumab, quantity: 213 mg - injection, concentrated - excipient ingredients: trometamol hydrochloride; sodium chloride; mannitol; pentetic acid; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - melanoma,yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma.,yervoy, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. the approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. all analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,renal cell carcinoma (rcc),yervoy, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,non-small cell lung cancer (nsclc),yervoy, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumour aberrations.,malignant pleural mesothelioma (mpm),yervoy, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,oesophageal squamous cell carcinoma (oscc),yervoy in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression greater than or equal to 1% as determined by a validated test.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - ipilimumab, quantity: 53.5 mg - injection, concentrated - excipient ingredients: trometamol hydrochloride; sodium chloride; mannitol; pentetic acid; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - melanoma,yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma.,yervoy, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. the approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. all analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,renal cell carcinoma (rcc),yervoy, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,non-small cell lung cancer (nsclc),yervoy, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumour aberrations.,malignant pleural mesothelioma (mpm),yervoy, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,oesophageal squamous cell carcinoma (oscc),yervoy in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression greater than or equal to 1% as determined by a validated test.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - fosinopril sodium -